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doi:10.1016/j.ejvs.2010.06.020Abstract Objectives: To describe duplex ultrasound (DUS) outcomes 12 months following
ultrasound-guided foam sclerotherapy (UGFS) of primary great saphenous varicose veins
(GSVV).
Methods: A consecutive series of UK National Health Service patients underwent serial DUS
examinations following UGFS with 3% sodium tetradecyl sulphate for symptomatic primary
GSVV.
Results: 344 treated legs (CEAP C2/3 237, C4 72, C5 14, C6 21) belonging to 278 patients (103
male) of median age 57 (range 21e89) years were enrolled between November 2004 and May
2007. The median volume of foam used was 10 (range 2e16) ml. Above-knee (AK) and below-
knee (BK) GSV reflux was present in 333 (96.8%) and 308 (89.5%) legs respectively prior to
treatment. AK and BK-GSV reflux was completely eradicated by a single session of UGFS in
323 (97.0%) and 294 (95.5%) legs respectively; and by two sessions of UGFS in 329 (98.8%)
and 304 (98.7%) legs respectively. In those legs where GSV reflux had been eradicated, reca-
nalisation occurred in 18/286 (6.3%) AK and 23/259 (8.9%) BK-GSV segments after 12 months
follow-up.
Conclusions: A single session of UGFS can eradicate reflux in the AK and BK-GSV in over 95%
of patients with symptomatic primary GSVV. Recanalisation at 12 months is superior to that
reported after surgery and similar to that observed following other minimally invasive tech-
niques.
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Superficial venous surgery (SVS) comprising ligation of the
saphenofemoral junction (SFJ), stripping of the above-knee
(AK) great saphenous vein (GSV) to the knee, and multiple
stab avulsions (MSA) appears to remain the preferred
treatment for symptomatic GSV varicose veins (GSVV)
among UK vascular surgeons.1
Although such surgery improves lower limb symptoms,
venous haemodynamics and health-related quality of life
(HRQL),2e6 it is associated with a significant incidence of
troubling and sometimes serious complications, morbidity,
delayed return to work and normal activities, as well as
medico-legal activity.6e16
Furthermore, previous studies of GSV stripping have
reported a significant primary technical failure and recur-
rence rate.3 Thus, despite best attempts to strip the GSV,
post-operative duplex not infrequently reveals reflux in
residual (remnant) GSV segments in the thigh and calf. Such
residual disease is a well-recognised cause of clinically
significant recurrent disease.17,18
Observational data suggest that the newer minimally
invasive techniques, such as ultrasound-guided foam scle-
rotherapy (UGFS), offer significant advantages over surgery
although durability, and specifically late recanalisation,
remains incompletely defined.11,19e22
The aim of this study is to describe duplex ultrasound
(DUS) outcomes 12 months following UGFS of primary GSVV.
Methods
Patients
Local medical ethics committee approval and written
informed consent were obtained. Consecutive patients
undergoing UGFS for symptomatic primary GSVV during
the study period of November 2004 and May 2007 were
enrolled in the study. All patients were NHS patients
referred to the Heart of England NHS Foundation Trust by
their general practitioners. All patients were assessed in
a consultant-led NHS outpatient clinic by one of two
consultant surgeons (DJA, AWB) prior to enrolment in the
study. To be considered suitable patients had to have
symptomatic venous disease (i.e. treatment was not
offered for cosmetic indications), to have significant
reflux (> 0.5 s) in the GSV confirmed on DUS, and no
previous history of GSV surgery on the same leg. Patients
with absent pedal pulses or an ankle-brachial pressure
index < 0.9 were excluded, as were those with post-
thrombotic deep venous disease.
Pre-treatment assessment
Patients were examined and the severity of venous disease
according to the CEAP clinical classification was deter-
mined.23 All patients had either visible varicosities (C2 or
C3) or skin complications (C4, C5 or C6). All patients
underwent DUS at their initial outpatient clinic appoint-
ment to identify sites of superficial and deep venous reflux.
All examinations were performed in a standard manner as
previously described.19UGFS treatment
The method of UGFS treatment has been described in detail
previously and is therefore summarised here.19 All treat-
ments were performed as outpatient procedures in
a treatment room, and each took less than 30 min. The
incompetent truncal veins and superficial varices were
marked on the skin using duplex imaging with the patient
standing, and then cannulae were inserted into the truncal
veins under direct ultrasonographic guidance with the
patient supine. The leg was then elevated for injection of
the sclerosant foam, prepared by a modified Tessari’s
method using two 2 ml syringes connected by a three-way
tap and a 5 micron filter (B Braun Medical, Sheffield, UK),
and comprising 0.5 ml of 3% sodium tetradecyl sulphate
(STS) (Fibrovein; STD Pharmaceuticals, Hereford, UK) and
2 ml of air.
With the leg still elevated a roll of Velband (Johnson
and Johnson Medical, Ascot, UK) was applied directly along
the line of the previously marked saphenous trunk and
superficial varices, and retained using Pehahaft cohesive
bandage (Hartmann, Heidenheim, Germany), and a thigh-
length class II compression stocking (Credelast; Creden-
hill, Ilkeston, UK) applied over the bandage. The bandaging
was left intact for five to ten days, depending on the size of
the veins, after which it was removed and the class II
stocking worn alone for a further three weeks. All patients
were provided with a 24 h “help-line” number to call at any
time following treatment in case of any concerns.Outcome measures and follow-up
The chosen outcome measure was complete occlusion of
the vein and eradication of venous reflux in the GSV on DUS.
All the patients were seen at 1, 6 and 12 months after
treatment in a dedicated research clinic. At the first visit
the patients were also asked whether they had had any
complications following their treatment. Patients were
specifically asked about visual disturbance, headache, and
possible nerve problems in the treated leg.
Repeat DUS was performed at each follow-up visit as per
the pre-treatment duplex. In addition, occlusion of the
treated saphenous trunk was assessed by a lack of
compressibility and the absence of any flow. Complete
occlusion was defined as occlusion over the entire length of
the GSV to the SFJ. Recanalisation was defined as the
presence of flow in either an antegrade or retrograde
direction in a previously occluded AK and/or below-knee
(BK) GSV. Recanalisation was considered complete if over
50% of the length of vein had recanalised. Where recanal-
isation was found, the presence or absence of recurrent
reflux was determined.
Patients with residual reflux or recanalisation at any
follow-up appointment were offered further treatment by
repeating foam sclerotherapy with 3% STS as outlined
above.
At each follow-up appointment treated limbs were also
examined to determine the presence of any visible trunk
VV. The presence of reticular veins only was not recorded
as clinical failure of treatment. The distribution (GSV,
AASV, or SSV) of any residual or recurrent VV was recorded.
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Patients and treatments
The characteristics of the 278 patients (344 legs) under-
going UGFS for primary GSVV are shown in Table 1. One,
two, three and four cannulae were used in 123, 202, 18, and
1 treatments respectively. The median volume of 3% STS
foam used at each treatment was 10 (range 2e16) ml. Ten
patients (12 legs) were taking warfarin (INR 2.5 to 3.5).
Three patients complained of visual disturbance shortly
after their injectionswhich consisted of blurring of vision and
in all cases lasted for less than10min.Therewasnodeepvein
thrombosis in this group of patients detected either clinically
or on follow-up DUS. There were no reported cases of
pulmonary embolism. There were no other complications.
Eradication of AK-GSV reflux
Complete eradication of reflux in the AK-GSV was achieved
in 323/333 (97.0%) legs after one, and in a further 6/333
(1.8%) legs after two treatment sessions (course of primary
treatment) (Fig. 1). In four legs (1.2%) complete eradication
of reflux in the AK-GSV was not achieved by one treatment
session but these patients, despite residual reflux in the AK-
GSV, were content with the clinical result and declined
further treatment sessions.
Eradication of BK-GSV reflux
Complete eradication of reflux in the BK-GSV was achieved
in 294/308 (95.5%) legs after one, and in a further 10/308
(3.2%) legs after two treatment sessions (course of primaryTable 1 Patient and disease characteristics.
Parameter 278 patients
(344 legs)
Age in years e median (range) 57 (21e89)
Sex
M 103 (37.1)
F 175 (62.9)
CEAP clinical grade
C2 213 (61.9)
C3 24 (7.0)
C4 72 (20.9)
C5 14 (4.1)
C6 21 (6.1)
Etiology
Primary (Ep) 344 (100)
Secondary (Es) 0 (0)
Anatomical patterns of venous reflux
Superficial and deep (Asd) 10 (2.9)
Superficial only (As) 334 (97.1)
Primary GSV above and below-knee 297 (86.3)
Primary GSV above-knee only 36 (10.5)
Primary GSV below-knee only 11 (3.2)
Pathophysiological classification
Reflux (Pr) 344 (100)
Obstruction (Po) 0 (0)treatment) (Fig. 2). In four legs (1.3%), complete eradica-
tion of reflux in the BK-GSV was not achieved by one
treatment session but these patients, despite residual
reflux in the BK-GSV, were content with the clinical result
and declined further treatment sessions.
Recanalisation of the AK-GSV
In the 329 legs in which the primary course of UGFS ach-
ieved complete eradication of the reflux in the AK-GSV,
recanalisation was observed in 7/295 (2.4%) legs at
6 months and 18/286 (6.3%) legs at 12 months (Fig. 1).
34 legs were not seen at 6 months; 43 at 12 months.
At 6 months this AK-GSV recanalisation was partial
(< 50%) without reflux in one leg and partial with reflux in
six legs. Of these seven legs, four underwent one session of
repeat UGFS which resulted in successful complete eradi-
cation of AK-GSV reflux, and three patients were content
with the clinical result and declined further treatment.
At 12 months this AK-GSV recanalisation was partial
without reflux in two legs, partial with reflux in 13 legs, and
complete (> 50%) with reflux in three legs. Of these 18 legs,
eight underwent one session of repeat UGFS which resulted
in successful complete eradication of AK-GSV reflux, and
ten were content with the clinical result and declined
further treatment.
Recanalisation of the BK-GSV
In the 304 legs in whom the primary course of UGFS ach-
ieved complete eradication of the reflux in the BK-GSV,
recanalisation was observed in 4/272 (1.5%) legs at
6 months and 23/259 (8.9%) legs at 12 months (Fig. 2). 32
legs were not seen at 6 months; 45 at 12 months.
At 6 months this BK-GSV recanalisation was complete
with reflux in all four legs. Of these four legs, three
underwent one session of repeat UGFS which resulted in
successful complete eradication of BK-GSV reflux, and one
patient was content with the clinical result and declined
further treatment.
At 12 months this BK-GSV recanalisation was partial
without reflux in one leg, partial with reflux in seven legs,
and complete with reflux in 15 legs. Of these 23 legs,
12 underwent one session of repeat UGFS which resulted in
successful complete eradication of BK-GSV reflux, and for
the remaining 11 legs the patient was content with the
clinical result and declined further treatment.
Clinical success
There were no visible VV in 304 legs (88.4%) after one
treatment, and in 316 legs (91.9%) after two treatment
sessions (course of primary treatment) to eradicate GSV
reflux. Six legs had residual GSV reflux in association with
residual VV after one session, but were happy with the
results and did not want further treatment. In 22 legs,
there were still some residual visible VV after successful
eradication of GSV reflux with just one session of treat-
ment. For six of these legs, no further treatment was
requested by the patient; and a single session of foam
injections directly into the visible varicosities successfully
Figure 1 Eradication of reflux and recanalisation in the above-knee great saphenous vein (AK-GSV).
Duplex Outcomes Following UGFS of Primary GSVV 537treated the residual VV in the remaining 16 legs, giving
a total of 332 legs (96.5%) with no visible VV after
a maximum of two treatment sessions.
By 12 months, 273/311 (87.8%) still had no visible VV
after their primary course of treatment (33 were lost to
follow-up or had residual untreated VV). Six legs had
recurrent VV in association with recanalisation at 6 months,
and 19 had recurrent VV in association with recanalisation
at 12 months. Fifteen of these 25 had further successful
UGFS treatment resulting in both eradication of the reflux
and disappearance of their recurrent VV; the remainder
were happy with the clinical results. Ten legs had a few
recurrent VV at 12 months but no recanalisation or reflux
and only two of these wanted further treatment; three had
VV secondary to new reflux in the SSV.Discussion
VV represent a chronic, frequently relapsing, condition that
develops secondary to valvular failure. It is, therefore, unre-
alistic to expect the complete and permanent eradication of
superficial reflux in all patients following a single treatment
whether that be surgical, UGFS, or anotherminimally invasive
alternative. This paradigm shift in the treatment of VV froma single event to a process has lead to a re-evaluation of
outcome measures and reporting standards.24,25
Although still considered by many surgeons as the “gold
standard”,1 it is widely recognised that residual and
recurrent GSV reflux are common after surgery for primary
GSVV.17 For example, MacKenzie and colleagues reviewed
66 patients two years after SFJ ligation and attempted GSV
stripping in the thigh and found that 62% had AK and 69%
had BK truncal reflux.3
Van Rij and colleagues prospectively followed-up
92 patients (127 limbs) after GSV surgery.18 At two weeks
after surgery, of 100 SFJ ligations only one had clearly failed,
with DUS demonstration of an intact SFJ. Clinical recurrence
in all limbswasprogressive, present in 13.7% (17/124) at three
months, 31.6% (36/114) at one year, and 51.7% (60/116) limbs
after three years. Of 100 SFJ that were adequately ligated, 23
demonstrated recurrent reflux at three years, with most of
the recurrences present by one year.
The effectiveness of GSV surgery is also limited by the
reluctance, based on fear of damaging the saphenous
nerve, to strip the BK-GSV; a common cause of residual and
recurrent disease. Furthermore, redo surgery for residual
or recurrent reflux is usually difficult, often morbid and
frequently associated with sub-optimal patient
outcomes.26
Figure 2 Eradication of reflux and recanalisation in the below-knee great saphenous vein (BK-GSV).
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be offered a primary course of UGFS treatments until all AK
and BK-GSV reflux has been eradicated. In most cases this
requires only one treatment session using a modest volume
of foam and is associated with a very low incidence of side-
effects and complications, and rapid return to work and
other activities.19 Furthermore, as also shown here, if
recurrent reflux develops as result of recanalisation that
disease can be very simply and effectively treated, usually
by a further single injection of foam.
One issue with UGFS is that the technique itself is far
from standardised and many variations on the basic theme
exist.27,28 We have honed our technique over almost
10 years and it continues to develop and we think improve.
For example, present data on eradication of GSV reflux
appear materially superior to those reported in a multi-
centre prospective trial of Varisolve  1% polidocanol
microfoam (Provensis, BTG, London, UK).29
In conclusion, the present paper adds further evidence
that UGFS is a safe and clinically and cost-effective treat-
ment for primary GSVV. A primary course of UGFS,
comprising one and infrequently two treatment sessions,
leads to complete eradication of GSV reflux in virtually
100% of cases. Recanalisation at 12 months is superior tothat reported after surgery and similar to that observed
following other minimally invasive techniques.Conflict of interest
None.
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